[Muroctasin, a muramyl dipeptide derivative].
This paper presents a review of studies on the metabolism, pharmacological and clinical properties of a new synthetic muramyl dipeptide derivative N2-/(N-acetylmuramoyl)-L-alanyl-D-isoglutaminyl/-N6-stearoyl-L-lysine(MD P- Lys(L18), muroctasin). Due to its effect on the number of peripheral blood leukocytes this compound is expected to be a useful drug for the treatment of leukopenia induced by cancer chemotherapy or radiation therapy.
Sosnowska
D
D
Katedra i Zakład Histologii Akademii Medycznej, Gdańsku.
Dzierzbicka
K
K
Myśliwski
A
A
Kołodziejczyk
A M
AM
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D005353:Fibronectins / Q000187:drug effects; D006410:Hematopoiesis / Q000187:drug effects; D006801:Humans; D007970:Leukopenia / Q000188:drug therapy
D005353:Fibronectins; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C036866:romurtide
Muroctasin, pochodna muramylodipeptydu.